Thioredoxin Reductase Activity Predicts Gold Nanoparticle Radiosensitization Effect.

biochemical mechanism gold nanoparticles prognosis radiation radiosensitization thioredoxin reductase

Journal

Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216

Informations de publication

Date de publication:
19 Feb 2019
Historique:
received: 30 01 2019
revised: 13 02 2019
accepted: 15 02 2019
entrez: 23 2 2019
pubmed: 23 2 2019
medline: 23 2 2019
Statut: epublish

Résumé

Gold nanoparticles (GNPs) have been shown to be effective contrast agents for imaging and emerge as powerful radiosensitizers, constituting a promising theranostic agent for cancer. Although the radiosensitization effect was initially attributed to a physical mechanism, an increasing number of studies challenge this mechanistic hypothesis and evidence the importance of oxidative stress in this process. This work evidences the central role played by thioredoxin reductase (TrxR) in the GNP-induced radiosensitization. A cell type-dependent reduction in TrxR activity was measured in five different cell lines incubated with GNPs leading to differences in cell response to X-ray irradiation. Correlation analyses demonstrated that GNP uptake and TrxR activity inhibition are associated to a GNP radiosensitization effect. Finally, Kaplan-Meier analyses suggested that high TrxR expression is correlated to low patient survival in four different types of cancer. Altogether, these results enable a better understanding of the GNP radiosensitization mechanism, which remains a mandatory step towards further use in clinic. Moreover, they highlight the potential application of this new treatment in a personalized medicine context.

Identifiants

pubmed: 30791480
pii: nano9020295
doi: 10.3390/nano9020295
pmc: PMC6409576
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fonds De La Recherche Scientifique - FNRS
ID : PhD grant

Références

Radiat Res. 2003 Mar;159(3):391-400
pubmed: 12600242
Phys Med Biol. 2004 Sep 21;49(18):N309-15
pubmed: 15509078
J Clin Oncol. 2005 Jan 20;23(3):422-31
pubmed: 15659489
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Clin Cancer Res. 2005 Dec 1;11(23):8425-30
pubmed: 16322305
J Biol Chem. 2006 May 12;281(19):13005-8
pubmed: 16565519
Semin Cancer Biol. 2006 Dec;16(6):420-6
pubmed: 17092741
PLoS One. 2007 Oct 31;2(10):e1112
pubmed: 17971875
Nanotechnology. 2009 Mar 18;20(11):115103
pubmed: 19420433
Cell Res. 2009 Aug;19(8):1031-4
pubmed: 19621033
Mutat Res. 2010 Apr-Jun;704(1-3):123-31
pubmed: 20074660
Nanotechnology. 2010 Feb 26;21(8):85103
pubmed: 20101074
Nanotechnology. 2010 Jul 23;21(29):295101
pubmed: 20601762
Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2089-98
pubmed: 20798378
Nanomedicine. 2011 Oct;7(5):604-14
pubmed: 21333754
Nanotechnology. 2008 Jul 23;19(29):295104
pubmed: 21730596
Nat Rev Clin Oncol. 2011 Aug 23;8(10):587-96
pubmed: 21862978
Appl Phys Lett. 2011 May 9;98(19):193702
pubmed: 21915155
Biomaterials. 2012 Sep;33(27):6408-19
pubmed: 22681980
Biosens Bioelectron. 2012 Oct-Dec;38(1):348-54
pubmed: 22776179
Cell Rep. 2013 Jan 31;3(1):260-73
pubmed: 23333277
Radiother Oncol. 2013 Jul;108(1):136-42
pubmed: 23647757
Sci Transl Med. 2013 May 22;5(186):186ra66
pubmed: 23698379
PLoS One. 2013 Sep 16;8(9):e74250
pubmed: 24066126
Anticancer Res. 2014 Jan;34(1):443-53
pubmed: 24403500
Cancer Res. 2014 May 1;74(9):2520-32
pubmed: 24599128
Cell Death Dis. 2014 Apr 24;5:e1191
pubmed: 24763048
Nanomedicine. 2014 Nov;10(8):1601-8
pubmed: 24846523
Small. 2014 Aug 27;10(16):3338-46
pubmed: 24863679
Nanomedicine. 2015 Jan;11(1):247-57
pubmed: 24983891
Phys Med Biol. 2014 Nov 7;59(21):6431-43
pubmed: 25296027
Phys Med. 2015 May;31(3):210-8
pubmed: 25651760
Sci Rep. 2015 Mar 02;5:8669
pubmed: 25727895
Cancer Nanotechnol. 2015;6(1):4
pubmed: 26345984
Oncotarget. 2015 Nov 3;6(34):36505-21
pubmed: 26431378
Nanotechnology. 2016 May 27;27(21):215101
pubmed: 27080849
Int J Nanomedicine. 2016 Apr 15;11:1549-56
pubmed: 27143877
Nanoscale. 2016 Jul 14;8(28):13627-37
pubmed: 27364973
Int J Radiat Biol. 2017 Mar;93(3):315-323
pubmed: 27690719
Nanotechnology. 2016 Nov 11;27(45):455101
pubmed: 27694702
Int J Nanomedicine. 2016 Oct 03;11:5003-5014
pubmed: 27757033
ACS Appl Mater Interfaces. 2017 Apr 19;9(15):13037-13048
pubmed: 28338323
Oncotarget. 2017 May 30;8(22):35728-35742
pubmed: 28415723
Med Phys. 2017 Aug;44(8):4299-4312
pubmed: 28543610
Cancer Nanotechnol. 2017;8(1):4
pubmed: 28757899
Oxid Med Cell Longev. 2017;2017:2597581
pubmed: 28770020
Nanoscale. 2017 Nov 30;9(46):18413-18422
pubmed: 29148554
Theranostics. 2018 Feb 12;8(7):1824-1849
pubmed: 29556359
Adv Healthc Mater. 2018 Aug;7(16):e1701460
pubmed: 29726118
Cell Death Dis. 2018 Jun 27;9(7):728
pubmed: 29950610
Nanomedicine (Lond). 2018 Nov;13(22):2917-2937
pubmed: 30427254
Nanomedicine (Lond). 2019 Feb;14(3):317-333
pubmed: 30675822

Auteurs

Sébastien Penninckx (S)

Research Center for the Physics of Matter and Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, B-5000 Namur, Belgium. sebastien.penninckx@unamur.be.

Anne-Catherine Heuskin (AC)

Research Center for the Physics of Matter and Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, B-5000 Namur, Belgium. anne-catherine.heuskin@unamur.be.

Carine Michiels (C)

Unité de Recherche en Biologie Cellulaire (URBC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, B-5000 Namur, Belgium. carine.michiels@unamur.be.

Stéphane Lucas (S)

Research Center for the Physics of Matter and Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, B-5000 Namur, Belgium. stephane.lucas@unamur.be.

Classifications MeSH